Discontinuation report VIZIMPRO
Report ID | 180956 |
Drug Identification Number | 02486040 |
Brand name | VIZIMPRO |
Common or Proper name | VIZIMPRO |
Company Name | PFIZER CANADA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | DACOMITINIB |
Strength(s) | 45MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 30's |
ATC code | L01EB |
ATC description | |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | |
Actual discontinuation date | 2023-01-13 |
Remaining supply date | 2023-01-13 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2023-01-14 | English | Compare |
v2 | 2023-01-13 | French | Compare |
v1 | 2023-01-13 | English | Compare |
Showing 1 to 3 of 3